ArticleInternational journal of clinical and experimental pathology2017
Clinical biocharacterization of immunophenotype in hepatocellular carcinoma patients.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In current observations, we investigated the clinical immunophenotypes in liver cells to assess the metastasic predisposition in advance hepatocellular carcinoma patients. In method, we harvested the clinically diagnosed data from 8 liver cancer subjects. Definitely, all patients were received standard chemotherapeutics when being confirmed as advanced liver cancer via clinical diagnosis. In parallel, biopsy liver samples were subjected to histopathological and immunoblotting assays. Representatively, clinical laboratory results showed that blood parameters resulted in notable elevations of aminotransferases (ALT, AST), hepatitis B e antibody (HBeAb), alpha-fetoprotein (APF) and carcinoembryonic antigen (CEA). In addition, immunoassays exhibited significant hepatocellular expressions of Ki-67 (cell proliferation), CD34 (angiogenesis), as well as strong production of CK8, CK10 (metastasis) in liver cells, as revealed in both the immunostaining and Western blotting analyses. Collectively, the present clinical findings elucidate that the metastasis of hepatocellular carcinoma relates to unregulated cell proliferation and angiogenesis. In particular, current representative immunophenotypes may be served as potential biomarkers for screening metastasis of advanced liver cancer.
Indexed as
Identifiers
31966612PMC6965218W3027812273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.